Get started
Work

Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease

Year: 2013
Type: article
Study design: Systematic Review
DOI: 10.1016/j.jacc.2013.09.042
Authors: Michelle L. O'Donoghue, David A. Morrow, Sotirios Tsimikas, Sarah Sloan, Angela F. Ren, Elaine B. Hoffman, Nihar R. Desai, Scott D. Solomon, Michael Domanski, Kiyohito Arai, Stephanie E. Chiuve, Christopher P. Cannon, Frank M. Sacks, Marc S. Sabatine
Institutions: Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group, University of California San Diego, Yale University, Yale New Haven Health System, Icahn School of Medicine at Mount Sinai, Tokyo Women's Medical University, Harvard University
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: bronze
Funders: Abbott Laboratories, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Brigham and Women's Hospital, Gilead Sciences, Alnylam Pharmaceuticals, CSL Behring, Regeneron Pharmaceuticals, Intarcia Therapeutics, BG Medicine, Fondation Leducq, Daiichi-Sankyo, Eisai, Servier, National Institutes of Health, Genentech, National Heart, Lung, and Blood Institute, Daiichi Sankyo Europe
Awards: G1781957139, G279324209, Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease, Metabolomic Biomarkers of Early Myocardial Injury, G9000284417, G985648046
OpenAlex ID: W1994699782
FWCI: 8.975
Cites: 45
Cited by: 215
Related to: 10